Net sales rose 18% year-over-year and operating loss narrowed, with the listed portfolio up 18.9% despite market volatility. Portfolio companies advanced clinical and research milestones, and management remains optimistic about long-term growth in medtech and life science.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.